natgillin/translations-raw huggingface dataset:
Placebo Linagliptin 5 mg Once 
Placebo Linagliptin 5 mg enkrat na dan
Continue to take Jentadueto as long as your doctor prescribes it so you can continue to help control your blood sugar. 
Zdravilo Jentadueto jemljite tako dolgo, kot vam bo vaš zdravnik predpisal, da boste dodatno uravnavali svoj krvni sladkor.
It does not stimulate insulin secretion and therefore does not produce hypoglycaemia. 
Ne stimulira izločanja insulina in tako ne povzroči hipoglikemije.
C] linagliptin dose to healthy subjects, approximately 85% of the administered radioactivity was eliminated in faeces (80%) or urine (5%) within 4 days of dosing. 
C]linagliptina se je pri zdravih preizkušancih približno 85 % radioaktivnosti izločilo z blatom (80 %) ali s sečem (5 %) v 4 dneh po dajanju.
The renal composite endpoint was defined as renal death or sustained end stage renal disease or sustained decrease of 40% or more in eGFR. 
Sestavljeni ledvični izid je bil opredeljen kot ledvična smrt ali trajna končna ledvična odpoved ali trajno znižanje oGFR za 40 % ali več.
There was no increased risk in hospitalization for heart failure which was an additional adjudicated endpoint observed compared to standard of care without linagliptin in patients with type 2 diabetes (table 4). 
Ni bilo povečanega tveganja za hospitalizacijo zaradi srčnega popuščanja, kar je bil dodatni ugotovljeni izid v primerjavi s standardno terapijo brez jemanja linagliptina pri bolnikih s sladkorno boleznijo tipa 2 (preglednica 4).
However, patients should be alerted to the risk of hypoglycaemia when Jentadueto is used in combination with other antidiabetic medicinal products known to cause hypoglycaemia (e.g. sulphonylureas). 
Bolnike je treba opozoriti na nevarnost hipoglikemije pri uporabi zdravila Jentadueto v kombinaciji z drugimi antidiabetiki, za katere je znano, da povzročajo hipoglikemijo (npr. sulfonilsečnine).
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction, 
• bolezni, ki lahko povzročijo tkivno hipoksijo (predvsem akutne bolezni ali poslabšanje kroničnih bolezni), kot so: dekompenzirano srčno popuščanje, odpoved dihal, nedavni miokardni infarkt, šok.
The intra-subject and inter-subject coefficients of variation for linagliptin AUC were small (12.6% and 28.5%, respectively). 
Koeficienti variacije AUC linagliptina med vsemi preizkušanci in pri posameznem so bili majhni (12,6 % oziroma 28,5 %).
In case of dehydration (severe diarrhoea or vomiting, fever or reduced fluid intake), metformin should be temporarily discontinued and contact with a health care professional is recommended. 
V primeru dehidracije (huda driska ali bruhanje, zvišana telesna temperatura ali zmanjšan vnos tekočine) je treba jemanje metformina začasno prekiniti; priporoča se posvet z zdravstvenim delavcem.
However, taking Jentadueto in combination with medicines called sulphonylureas or with insulin can cause too low blood sugar level (hypoglycaemia), which may affect your ability to drive and use machines or work without safe foothold. 
Toda jemanje zdravila Jentadueto v kombinaciji z zdravili, ki jih imenujemo sulfonilsečnine ali z insulinom, lahko povzroči premočno znižanje ravni krvnega sladkorja (hipoglikemijo), ki lahko zmanjša vašo sposobnost za vožnjo in uporabo strojev ali delo brez varne opore na tleh.
- Metformin belongs to a class of medicines called biguanides. 
- Metformin je zdravilna učinkovina iz skupine zdravil, poimenovane bigvanidi.
Your doctor may prescribe a medicine to treat your allergic reaction and a different medicine for your diabetes. 
Zdravnik vam bo predpisal zdravilo za alergijsko reakcijo in izbral drugo zdravilo za sladkorno bolezen.
GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. 
GLP-1 in GIP povečata biosintezo in izločanje insulina iz celic beta trebušne slinavke, in sicer pri normalni in zvišani ravni glukoze v krvi.
The unbound concentrations, which are usually less than 1% at the therapeutic dose of linagliptin, were increased 4-5-fold after co-administration with ritonavir. 
Nevezane koncentracije, ki so običajno pri terapevtskem odmerjanju linagliptina manjše od 1 %, so se povečale za 4- do 5-krat pri sočasnem dajanju z ritonavirjem.
The incidence of hypoglycaemia in the linagliptin group (7.5%) was significantly lower than that in the glimepiride group (36.1%). 
Pojavnost hipoglikemije je bila v skupini, ki je jemala linagliptin (7,5 %), pomembno manjša kot v tisti, ki je jemala glimepirid (36,1 %).
Metformin is contraindicated in patients with GFR<30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function, see section 4.3). 
Metformin je kontraindiciran pri bolnikih z GFR< 30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic, glejte poglavje 4.3.
After oral administration, metformin hydrochloride absorption is saturable and incomplete. 
Po peroralni uporabi je absorpcija metforminijevega klorida saturabilna in nepopolna.
Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and NSAIDs) should be initiated with caution in metformin-treated patients. 
Zdravila, ki lahko akutno okvarijo delovanje ledvic (kot so antihipertenzivi, diuretiki in nesteroidna protivnetna zdravila), je treba pri bolnikih, ki se zdravijo z metforminom, uvesti previdno.
Oral 2 year carcinogenicity studies in rats and mice revealed no evidence of carcinogenicity in rats or male mice. 
Dveletne študije o karcinogenosti peroralnih odmerkov pri podganah in miših niso izkazale karcinogenega delovanja pri podganah ali mišjih samcih.
Renal clearance of metformin hydrochloride is > 400 ml/min, indicating that metformin hydrochloride is eliminated by glomerular filtration and tubular secretion. 
Ledvični očistek metforminijevega klorida je > 400 ml/min, kar kaže, da se metforminijev klorid izloča z glomerulno filtracijo in tubulno sekrecijo.
Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs, ATC code: A10BD11 
Farmakoterapevtska skupina: zdravila za zdravljenje diabetesa,kombinacije peroralnih antidiabetikov, oznaka ATC: A10BD11
Effects of linagliptin on other medicinal products 
Učinki linagliptina na druga zdravila
For patients with acute and unstable heart failure, Jentadueto is contraindicated (see section 4.3). 
Pri bolnikih z akutnim in nestabilnim srčnim popuščanjem je zdravilo Jentadueto kontraindicirano (glejte poglavje 4.3).
Linagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. 
Linagliptin je šibak kompetitivni in glede na mehanizem delovanja šibak do zmeren zaviralec izocima CYP3A4, vendar drugih izocimov CYP ne zavira.
Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in cases of fasting, malnutrition or hepatic impairment. 
Zastrupitev z alkoholom je povezana s povečanim tveganjem za laktacidozo, zlasti ob postenju, podhranjenosti ali okvari jeter.
Based on these results and in vivo drug interaction studies, linagliptin is considered unlikely to cause interactions with other P-gp substrates. 
Na podlagi teh izsledkov in podatkov študij o medsebojnem delovanju in vivo ni verjetno, da bi linagliptin povzročal interakcije z drugimi substrati P-glikoproteina.
Other risk factors for lactic acidosis are excessive alcohol intake, hepatic impairment, inadequately controlled diabetes, ketosis, prolonged fasting and any conditions associated with hypoxia, as well as concomitant use of medicinal products that may cause lactic acidosis (see sections 4.3 and 4.5). 
Drugi dejavniki tveganja za laktacidozo so pretirano uživanje alkohola, jetrna insuficienca, neustrezno nadzorovana sladkorna bolezen, ketoza, dolgotrajno postenje in vsa stanja, povezana s hipoksijo, ter sočasna uporaba zdravil, ki lahko povzročijo laktacidozo (glejte poglavji 4.3 in 4.5).
Renal clearance at steady-state was approximately 70 ml/min. 
Ledvični očistek v stanju dinamičnega ravnovesja je bil približno 70 ml/min.
• in combination with other medicinal products for the treatment of diabetes, including insulin, in patients inadequately controlled with metformin and these medicinal products 
• v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni, vključno z insulinom, pri bolnikih z nezadostno urejeno boleznijo pri jemanju metformina v kombinaciji z drugimi zdravili;
During controlled clinical trials in healthy subjects, single doses of up to 600 mg linagliptin (equivalent to 120 times the recommended dose) were not associated with a dose dependent increase in adverse events. 
V nadzorovanih kliničnih preskušanjih pri zdravih prostovoljcih enkratni odmerki do 600 mg linagliptina (ustreza 120-kratnemu priporočenemu odmerku) niso bili povezani z z odmerkom odvisnim povečanjem neželenih učinkov.
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Jentadueto before or at the time of the injection. 
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Jentadueto.
Stop taking Jentadueto for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. 
Za kratek čas prenehajte jemati zdravilo Jentadueto, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
Single dose study: after single doses of metformin hydrochloride 500 mg, paediatric patients have shown a similar pharmacokinetic profile to that observed in healthy adults. 
Študija z enkratnim odmerkom: po dajanju enkratnih odmerkov metforminijevega klorida 500 mg je bil farmakokinetični profil pri pediatričnih bolnikih podoben tistemu pri zdravih odraslih.
If you are overweight, continue your energy-restricted diet as instructed. 
Če imate preveliko telesno maso, po navodilih nadaljujte z dieto z zmanjšano energijsko vrednostjo.
As metformin is excreted by the kidney, Jentadueto should be used with caution as age increases. 
Ker se metformin izloča skozi ledvice, je treba zdravilo Jentadueto previdno uporabljati pri starejših bolnikih.
The clinical trials before marketing authorization have been performed up to a BMI equal to 40 kg/m 
Klinična preskušanja, ki so jih opravili pred izdajo dovoljenja za promet, so zajela bolnike z indeksom telesne mase do 40 kg/m
Patients with heart failure are more at risk of hypoxia and renal impairment. 
Pri bolnikih s srčnim popuščanjem obstaja večje tveganje za hipoksijo in ledvično okvaro.
Not all pack sizes may be marketed in your country. 
Na trgu v vaši državi morda ni vseh navedenih pakiranj.
STOP taking Jentadueto and contact a doctor immediately if you notice any of the following serious side effects: - Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas 
Takoj PRENEHAJTE jemati zdravilo Jentadueto in se posvetujte z zdravnikom, če opazite katerega od naslednjih resnih neželenih učinkov: - huda in persistentna trebušna bolečina (v predelu želodca), ki se lahko širi v hrbet; tudi slabost in bruhanje, ker so vsi lahko tudi znaki vnetja trebušne slinavke (pankreatitisa).
No dose adjustment 
Brez prilagajanja odmerka.
It contains two different active substances linagliptin and metformin. 
Vsebuje dve različni zdravilni učinkovini, linagliptin in metformin.
A paediatric Phase 2 study examined the pharmacokinetics and pharmacodynamics of 1 mg and 5 mg linagliptin in children and adolescents ≥10 to <18 years of age with type 2 diabetes mellitus. 
V pediatrični študiji faze 2 so preučevali farmakokinetiko in farmakodinamiko 1 mg in 5 mg linagliptina pri otrocih in mladostnikih s sladkorno boleznijo tipa 2, starih ≥ 10 do < 18 let.
A significantly higher incidence of malignant lymphomas only in female mice at the highest dose (> 200 times human exposure) is not considered relevant for humans (explanation: nontreatment related but due to highly variable background incidence). 
Pomembno večja pojavnost malignih limfomov, ki so jo odkrili samo pri mišjih samicah pri največjih odmerkih (preko 200-krat večje kot za človeka), pa ni pomembna za ljudi (pojasnilo: pojavnost ni bila povezana z zdravljenjem, temveč z močno spremenljivo osnovno pojavnostjo).
What Jentadueto looks like and contents of the pack 
Izgled zdravila Jentadueto in vsebina pakiranja
Race had no obvious effect on the plasma concentrations of linagliptin based on a composite analysis of available pharmacokinetic data, including patients of Caucasian, Hispanic, African, and Asian origin. 
Rasa ni zaznavno vplivala na koncentracijo linagliptina v plazmi, kar je pokazala sestavljena analiza razpoložljivih farmakokinetičnih podatkov, ki je zajela bolnike bele rase ter latinskoameriškega, afriškega in azijskega izvora.
If a dose is missed, it should be taken as soon as the patient remembers. 
Če bolnik pozabi vzeti odmerek, ga mora vzeti takoj, ko se spomni.
Therefore, clinically relevant interactions would not be expected with other P-glycoprotein/CYP3A4 inhibitors. 
Zato niso verjetne klinično pomembne interakcije z drugimi zaviralci P-glikoproteina ali CYP3A4.
If pancreatitis is suspected, Jentadueto should be discontinued; if acute pancreatitis is confirmed, Jentadueto should not be restarted. 
Pri sumu na pankreatitis je treba zdravljenje z zdravilom Jentadueto prekiniti; če je akutni pankreatitis potrjen, zdravljenja z zdravilom Jentadueto ni dovoljeno nadaljevati.
General toxicity studies in rats for up to 13 weeks were performed with the co-administration of linagliptin and metformin. 
V študijah splošne toksičnosti, ki so jih do 13 tednov izvajali pri podganah, so dajali linagliptin in metformin sočasno.
• Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin. 
• induktorji OCT1 (npr. rifampicin) lahko poveča obseg gastrointestinalne absorpcije in učinkovitost metformina,
NAME OF THE MARKETING AUTHORISATION HOLDER Boehringer Ingelheim (Logo) 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Boehinger Ingelheim (logotip)
It is assumed that the pharmacokinetics of metformin hydrochloride absorption are non-linear. 
Domnevajo, da je farmakokinetika absorpcije metforminijevega klorida nelinearna.
Simulations of steady-state plasma concentrations of linagliptin with and without ritonavir indicated that the increase in exposure will not be associated with an increased accumulation. 
Simulacije koncentracije linagliptina v plazmi v stanju dinamičnega ravnovesja ob prisotnosti ritonavirja in brez njega so pokazale, da povečane izpostavljenosti ne spremlja povečano kopičenje.
If this happens to you, you may need immediate hospital treatment, as lactic acidosis can lead to coma. 
Če se pri vas pojavijo ti simptomi, boste morda potrebovali takojšnje bolnišnično zdravljenje, saj lahko laktacidoza vodi v komo.
500 mg Twice Daily 
500 mg dvakrat na dan
- Film coating: hypromellose, titanium dioxide (E171), talc, propylene glycol. 
Filmska obloga: hipromeloza, titanov dioksid (E171), smukec, propilenglikol.
Some symptoms need immediate medical attention You should stop taking Jentadueto and see your doctor straight away if you experience the following symptoms of low blood sugar (hypoglycaemia): trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change, or confusion. 
Pri pojavu nekaterih simptomov je potrebna takojšnja zdravniška oskrba Zdravilo Jentadueto morate takoj prenehati jemati in obiskati zdravnika, če se pojavijo znaki nizkega krvnega sladkorja (hipoglikemije): tresenje, znojenje, anksioznost, meglen vid, mravljinci v ustnicah, bledica, sprememba razpoloženja ali zmedenost.
• Acute conditions with the potential to alter renal function such as: dehydration, severe infection, 
• akutna stanja, pri katerih se lahko spremeni ledvično delovanje, kot so: dehidracija, huda okužba, šok
Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function or cardiorespiratory illness or sepsis. 
Laktacidoza, zelo redek a resen presnovni zaplet, se najpogosteje pojavi ob akutnem poslabšanju delovanja ledvic, ob kardiorespiratorni bolezni ali sepsi.
1,000 mg Twice Daily 
1000 mg dvakrat na dan
If you are not sure, talk to your doctor or pharmacist before taking this medicine. 
Če ste v dvomih, se pogovorite s svojim zdravnikom ali farmacevtom, preden boste vzeli to zdravilo.
These changes in linagliptin pharmacokinetics were not considered to be clinically relevant. 
Opisane spremembe farmakokinetike linagliptina niso klinično pomembne.
The study population included 2089 (35%) patients with cardiovascular disease and 1130 (19%) patients with renal impairment with an eGFR < 60ml/min/1.73m2 at baseline. 
Študijska populacija je vključevala 2089 (35 %) bolnikov s srčno-žilno boleznijo in 1130 (19 %) bolnikov z ledvično okvaro, ki so imeli izhodiščni eGFR < 60 ml/min/1,73 m2.
At the recommended metformin hydrochloride doses and dosing schedules, steady-state plasma concentrations are reached within 24 to 48 hours and are generally less than 1 microgram/ml. 
Pri uporabi priporočenih odmerkov po shemah odmerjanja doseže metforminijev klorid koncentracijo v stanju dinamičnega ravnovesja v plazmi v 24 do 48 urah in je na splošno manjša od 1 μg/ml.
• Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprime, vandetanib, 
• zaviralci OCT2 (npr. cimetidin, dolutegravir, ranolazin, trimetoprim, vandetanib, izavukonazol)
Metformin hydrochloride partitions into erythrocytes. 
Metforminijev klorid se porazdeli v eritrocite.
In analyses for albuminuria progression (change from normoalbuminuria to micro- or macroalbuminuria, or from microalbuminuria to macroalbuminuria) the estimated hazard ratio was 0.86 (95% CI 0.78, 0.95) for linagliptin versus placebo. 
Pri analizah napredovanja albuminurije (sprememba z normoalbuminurije v mikro- ali makroalbuminurijo ali z mikroalbuminurije v makroalbuminurijo) je bilo ocenjeno razmerje tveganja 0,86 (95-% IZ 0,78; 0,95) za linagliptin v primerjavi s placebom.
As a result of tissue binding, the mean apparent volume of distribution at steady-state following a single 5 mg intravenous dose of linagliptin to healthy subjects is approximately 1110 litres, indicating that linagliptin extensively distributes to the tissues. 
Zaradi tkivne vezave je srednji navidezni volumen porazdelitve v stanju dinamičnega ravnovesja po enem intravenskem odmerku 5 mg linagliptina pri zdravih prostovoljcih približno 1.110 litrov, kar kaže, da se linagliptin obsežno porazdeli v tkiva.
The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of 5 mg linagliptin, is approximately 12 hours. 
Efektivna razpolovna doba za kopičenje linagliptina, določena pri peroralnem dajanju večkratnih odmerkov po 5 mg, je približno 12 ur.
Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC (area under the curve) and a 35 minute prolongation of the time to peak plasma concentration were observed. 
Po dajanju odmerka po 850 mg so izmerili za 40 % manjšo največjo koncentracijo v plazmi, za 25 % manjšo AUC (površino pod krivuljo) in za 35 minut podaljšan čas do največje koncentracije v plazmi.
Approximately 19% of the population had eGFR ≥45 to <60 mL/min/1.73 m2, 28% of the population had eGFR ≥30 to <45 mL/min/1.73 m2) and 15% 
Približno 19 % populacije je imelo oGFR med ≥ 45 in < 60 ml/min/1,73 m2, 28 % populacije je imelo oGFR med ≥ 30 in < 45 ml/min/1,73 m oGFR pri 15 % populacije pa je znašal < 30 ml/min/1,73 m2.
Co-administration with other potent inducers of P-glycoprotein and CYP3A4, such as carbamazepine, phenobarbital and phenytoin has not been studied. 
Sočasno dajanje z drugimi močnimi induktorji P-glikoproteina in CYP3A4, na primer s karbamazepinom, fenobarbitalom in fenitoinom, ni raziskano.
Hypoglycaemia may occur when Jentadueto is administered together with sulphonylurea (≥ 1 case per 10 patients). 
Hipoglikemija se lahko pojavi, če jemlje bolnik zdravilo Jentadueto hkrati s sulfonilsečnino (≥ 1 primer na 10 bolnikov).
In clinical studies, as described below, linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT). 
V opisanih kliničnih študijah linagliptin ni klinično pomembno vplival na farmakokinetiko metformina, gliburida, simvastatina, varfarina, digoksina ali peroralnih kontraceptivov, kar je kazalec in vivo, da je možnost povzročanja interakcij zdravila s substrati CYP3A4, CYP2C9, CYP2C8, P-glikoproteina in organskih kationskih prenašalcev (organic cationic transporter - OCT) majhna.
Gastrointestinal disorders such as, nausea, vomiting, diarrhoea and decreased appetite and abdominal pain occur most frequently during initiation of therapy with Jentadueto or metformin hydrochloride and resolve spontaneously in most cases. 
Bolezni prebavil, kot so navzea, bruhanje, driska in zmanjšan tek ter trebušna bolečina, se najpogosteje pojavljajo na začetku zdravljenja z zdravilom Jentadueto ali metforminijevim kloridom ter večinoma spontano minejo.
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. 
Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko poveča tveganje za laktacidozo, npr. nesteroidna protivnetna zdravila, vključno s selektivnimi zaviralci ciklooksigenaze (COX) II, zaviralci ACE, antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
This medicine alone is unlikely to cause abnormally low blood sugar (hypoglycaemia). 
Ni verjetno, da bi to zdravilo samo znižalo raven krvnega sladkorja na prenizko vrednost (hipoglikemija).
The study was designed to demonstrate non-inferiority for the primary cardiovascular endpoint which was a composite of the first occurrence of cardiovascular death or a non-fatal myocardial infarction (MI) or a non-fatal stroke (3P-MACE). 
Namen študije je bil pokazati neinferiornost primarnega srčno-žilnega izida, sestavljenega iz prvega pojava srčno-žilne smrti ali neusodnega miokardnega infarkta (MI) ali neusodne možganske kapi (3P-MACE).
They have "D2/850" debossed on one side and the Boehringer Ingelheim logo debossed on the other. 
Na eni strani imajo vtisnjeno oznako “D2/850”, na drugi pa logotip Boehringer Ingelheim.
Hypoglycaemia has not been seen with metformin hydrochloride doses of up to 85 g, although lactic acidosis has occurred in such circumstances. 
Pri odmerkih metforminijevega klorida do 85 g niso zasledili hipoglikemije, se je pa pri teh odmerkih pojavila laktacidoza.
If you take more Jentadueto than you should 
Če ste vzeli večji odmerek zdravila Jentadueto, kot bi smeli
They have "D2/1000" debossed on one side and the Boehringer Ingelheim logo debossed on the other. 
Na eni strani imajo vtisnjeno oznako “D2/1000”, na drugi pa logotip Boehringer Ingelheim.
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable. 
Zdravljenje se sme ponovno uvesti najmanj 48 ur po kirurškem posegu ali začetku peroralnega prehranjevanja, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno.